← Dashboard
Stock
BIIB
BIOGEN INC.Health CareBiotechnologyLatest close $1897 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
14
Current + past
New this quarter
0
Exited this quarter
1
Marquee-fund ownership over time
Aug 13, 2013May 11, 2017Nov 15, 2021May 15, 2026
Now
7
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $202 | $189 | -7% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $201 | $189 | -6% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $201 | $189 | -6% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $201 | $189 | -6% |
| Citadel Advisors | Q4 2024(8Q snapshot) | 6Q | $165 | $189 | +14% |
| Point72 Asset Management | Q2 2025(8Q snapshot) | 4Q | $124 | $189 | +52% |
| Glenview Capital | Q1 2026 | 1Q | $196 | $189 | -4% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| D.E. Shaw | Q3 2024 | Q2 2026 | → $193 | -4% |
| Bridgewater Associates 7× in & out | Q4 2025 | Q1 2026 | → $197 | +19% |
| Maverick Capital 6× in & out | Q1 2024 | Q2 2024 | → $235 | +7% |
| Berkshire Hathaway | Q1 2020 | Q3 2021 | → $344 | +3% |
| Scion Asset Management | Q1 2019 | Q2 2019 | → $231 | -29% |
| Duquesne Family Office 3× in & out | Q4 2017 | Q2 2018 | → $276 | -11% |
| Viking Global Investors 4× in & out | Q1 2016 | Q3 2017 | → $286 | +12% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BIOGEN INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
1
Filings · last 90d
22
Total on file
616
Recent SEC buffer
Most recent
May 5, 2026
30d / 90d windows measured from May 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40000875045-26-000046May 5, 2026
- Form 40000875045-26-000036Apr 3, 2026
- Form 40000875045-26-000035Feb 17, 2026
- Form 40000875045-26-000034Feb 17, 2026
- Form 40000875045-26-000033Feb 17, 2026
- Form 40000875045-26-000032Feb 17, 2026
- Form 40000875045-26-000031Feb 17, 2026
- Form 40000875045-26-000030Feb 17, 2026
- Form 40000875045-26-000029Feb 17, 2026
- Form 40000875045-26-000028Feb 17, 2026
- Form 40000875045-26-000027Feb 17, 2026
- Form 40000875045-26-000026Feb 17, 2026
- Form 40000875045-26-000024Feb 10, 2026
- Form 40000875045-26-000023Feb 10, 2026
- Form 40000875045-26-000022Feb 10, 2026
Showing 15 of 616 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · BIOGEN INC.Annual figures sourced directly from BIOGEN INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$9.89B
FY2025+2% YoY
Net income
$1.29B
FY2025-21% YoY
EPS (diluted)
$8.79
FY2025-21% YoY
Free cash flow(?)
$2.05B
FY2025-25% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BIOGEN INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 14, 2026
- 10-QQuarterly reportApr 29, 2026
- 8-KMaterial eventApr 29, 2026
- DEF 14AProxy statementApr 28, 2026
- 8-KMaterial eventApr 6, 2026
- 8-KMaterial eventMar 31, 2026
- 8-KCURRENT REPORTMar 11, 2026
- 8-KMaterial eventFeb 11, 2026
- 10-KAnnual reportFeb 6, 2026
- 8-KMaterial eventFeb 6, 2026
- 8-KMaterial eventJan 14, 2026
- 10-QQuarterly reportOct 30, 2025
- 8-KMaterial eventOct 30, 2025
- 8-KMaterial eventOct 14, 2025
- 8-KMaterial eventJul 31, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Glenview Capital | Q1 2026 | open | $196 | $192 | -2% |
| Bridgewater Associates | Q4 2025 | Q1 2026 | $165 | $197 | +19% |
| Point72 Asset Management | Q2 2025 | open | $124 | $192 | +55% |
| Citadel Advisors | Q4 2024 | open | $165 | $192 | +16% |
| Two Sigma Investments | Q3 2024 | open | $201 | $192 | -4% |
| D.E. Shaw | Q3 2024 | Q2 2026 | $201 | $193 | -4% |
| AQR Capital Management | Q3 2024 | open | $201 | $192 | -4% |
| Millennium Management | Q3 2024 | open | $201 | $192 | -4% |
| Renaissance Technologies | Q3 2024 | open | $202 | $192 | -5% |
| Maverick Capital | Q1 2024 | Q2 2024 | $221 | $235 | +7% |
| Maverick Capital | Q3 2023 | Q4 2023 | $273 | $225 | -17% |
| Maverick Capital | Q4 2021 | Q1 2022 | $272 | $214 | -21% |
| Bridgewater Associates | Q2 2021 | Q2 2025 | $280 | $120 | -57% |
| Maverick Capital | Q3 2020 | Q1 2021 | $289 | $279 | -3% |
| Berkshire Hathaway | Q1 2020 | Q3 2021 | $333 | $344 | +3% |
| Maverick Capital | Q4 2019 | Q1 2020 | $275 | $333 | +21% |
| Scion Asset Management | Q1 2019 | Q2 2019 | $325 | $231 | -29% |
| Bridgewater Associates | Q2 2018 | Q1 2020 | $276 | $334 | +21% |
| Duquesne Family Office | Q4 2017 | Q2 2018 | $310 | $276 | -11% |
| Bridgewater Associates | Q2 2017 | Q1 2018 | $254 | $317 | +25% |
| Maverick Capital | Q2 2016 | Q4 2017 | $266 | $310 | +16% |
| Viking Global Investors | Q1 2016 | Q3 2017 | $257 | $286 | +12% |
| Bridgewater Associates | Q4 2015 | Q1 2017 | $291 | $275 | -6% |
| Viking Global Investors | Q3 2015 | Q4 2015 | $313 | $284 | -9% |
| Bridgewater Associates | Q4 2014 | Q3 2015 | $321 | $315 | -2% |
| Duquesne Family Office | Q3 2014 | Q3 2015 | $337 | $313 | -7% |
| Viking Global Investors | Q2 2014 | Q3 2014 | $290 | $337 | +16% |
| Viking Global Investors | Q3 2013 | Q1 2014 | $212 | $328 | +55% |
| Duquesne Family Office | Q3 2013 | Q2 2014 | $212 | $297 | +40% |
| Bridgewater Associates | Q3 2013 | Q2 2014 | $211 | $297 | +40% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.